Clinical trial sponsors were preoccupied with speeding up studies and enhancing the trial experience for key stakeholders before the global pandemic. In this endeavor, decentralization has emerged as a key factor. As the pandemic spread, patients flooded healthcare facilities and hampered clinical trials, but it also enhanced Veristat oncology trial design and accelerated the deployment of decentralized solutions.
The research industry has since then been obliged to implement decentralized oncology clinical trial design and solutions to solve growing issues with distant trial activities and engage with patients and stakeholders. Although the pandemic still lingers, reports show that decentralized trials are here to stay. With this being the undeniable case, what does the future hold for decentralized clinical trials?
It’s easy to get caught up in the euphoria of how technology enabled so much during such a pivotal period in history. And these new research approaches such as oncology clinical trial design may become permanent, supplementing previous means of surveillance. The pandemic has brought to light the advantages of remote clinical trials in two phases: Remote monitoring is both practicable and efficient. Also, monitoring on-site is extremely cost-effective. On-site monitors can have strategic conversations and problem-solving sessions during site visits thanks to remote monitoring. Rather than sitting in a room staring at documents, the researcher may monitor procedures and correct protocol violations.
Remote Specimens Collection
Since this strategy allows participants to remain safe at home, remote, patient-centric blood microsampling has shown to be a successful solution for assisting clinical studies along a virtual pathway. Participants can avoid difficult travel and discomfort by participating in virtual clinical studies. Participants no longer need to visit clinics or labs for traditional blood draws with healthcare personnel thanks to remote sample devices that anybody can utilize. With remote sampling devices, participants can easily obtain the required samples at home and ship them to the lab for examination. These devices are meant to collect small samples, therefore, removing the stress and discomfort associated with traditional research methods.
Remote Blood Sampling
Implementing the remote blood collection strategy reduces the need for expensive and difficult delivery procedures. Patients just collect their samples at home at predetermined intervals and mail them in the sealed pouch and envelope provided. This method of remote, minimally intrusive blood sampling reduces clinic visits while maintaining accurate clinical trial monitoring. Remote blood collection allows for virtual trials and helps overcome a variety of objections, making subject recruitment and retention easier. Overall, this process makes clinical trials more efficient.
Virtual clinical trials follow the same safety regulations as traditional clinical trials.
The US Food and Drug Administration (FDA) only allows highly regulated clinical studies, whether they are virtual or on-site. Still, people need to engage in trials to see how successful a medication, vaccination, or gadget is in different groups, and virtual clinical trials make it easier to do so.
The future of virtual clinical Trials is bright and promising. it will make trials more effective and efficient clinical trials with reduced downtime.